QLT Shows Positive 4 Week Efficacy in Phase II Study for Glaucoma Using Latanoprost Punctal Plug Delivery System
August 30, 2011
Submit Comments
QLT Inc. yesterday announced results of its Phase II clinical study on the efficacy and safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in subjects with ocular hypertension (OH) and open-angle glaucoma (OAG).
The results were promising with the study representing the first reported demonstration of a clinically significant, prolonged (4 weeks) reduction in intraocular pressure (IOP) in glaucoma with an extraocular, minimally-invasive sustained release ophthalmic drug delivery system.
Click here for the full release.
You might also enjoy...
- QLT Announces Phase II Clinical Trial Results for the Olopatadine Punctal Plug Delivery System
- Does a Modest Reduction in Intraocular Pressure Slow Vision Loss in Glaucoma Patients?
- QLT Announces Interim Data for Phase 2 Punctal Plug Delivery System Clinical Trial
- Transcend Medical Raises $35 Million for Development of CyPass Glaucoma Treatment System
- Roche and Genentech Strike Deal With Surmodics For Biodegradable Microparticle Drug Delivery System for Lucentis
Comments
Jump down to form below to submit your own comments
